Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki.
Department of Nephrology, Nagasaki University Hospital, Nagasaki.
Rheumatology (Oxford). 2021 May 14;60(5):2333-2341. doi: 10.1093/rheumatology/keaa599.
We aimed to compare life prognosis and renal relapse after induction therapy in proliferative (PLN) and pure membranous LN (MLN).
We retrospectively analysed the cases of 140 of 172 patients with LN who underwent a renal biopsy at our hospital or community hospitals from 1993 to 2016. We determined the complete response (CR) rate at 12 months after the patients had started induction therapy, and we evaluated the predictive factors for CR, life prognosis and renal relapse in PLN and pure MLN. We defined PLN as International Society of Neurology and the Renal Pathology Society (ISN/RPS) Class III or IV and MLN as ISN/RPS Class V.
The renal pathology of 99 (70.7%) patients was classified as PLN, and that of the other 41 (29.3%) patients as MLN. Fifty patients (50.5%) with PLN and 22 patients (53.7%) with MLN achieved a CR at 12 months. A multivariate analysis showed that a lower index of chronicity in PLN and a higher total haemolytic complement (CH50) level in MLN were predictive factors for achieving a CR at 12 months. A Kaplan-Meier analysis showed that the life prognosis (P = 0.93) and renal relapse (P = 0.52) were not significantly different between PLN and MLN.
The predictive factors for a CR at 12 months post-induction therapy were index of chronicity in PLN and CH50 level in MLN. There were no significant differences in life prognosis or renal relapse between PLN and MLN in the achievement of a CR at 12 months post-induction therapy.
比较增生性(PLN)和单纯膜性(MLN)狼疮性肾炎(LN)患者诱导治疗后的预后和肾脏复发情况。
我们回顾性分析了 1993 年至 2016 年期间在我院和社区医院接受肾活检的 172 例 LN 患者中的 140 例。我们确定了患者开始诱导治疗后 12 个月的完全缓解(CR)率,并评估了 PLN 和单纯 MLN 中 CR、生存预后和肾脏复发的预测因素。我们将 PLN 定义为国际神经病学和肾脏病理学会(ISN/RPS)III 或 IV 级,MLN 定义为 ISN/RPS V 级。
99 例(70.7%)患者的肾病理为 PLN,41 例(29.3%)患者为 MLN。50 例(50.5%)PLN 患者和 22 例(53.7%)MLN 患者在 12 个月时达到 CR。多变量分析显示,PLN 中慢性指数较低和 MLN 中总补体溶血(CH50)水平较高是 12 个月时达到 CR 的预测因素。Kaplan-Meier 分析显示,PLN 和 MLN 达到 CR 后 12 个月的生存预后(P=0.93)和肾脏复发(P=0.52)无显著差异。
PLN 中慢性指数和 MLN 中 CH50 水平是诱导治疗后 12 个月时达到 CR 的预测因素。在诱导治疗后 12 个月达到 CR 时,PLN 和 MLN 之间的生存预后或肾脏复发无显著差异。